Share This Page
ALPHADERM Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Alphaderm, and when can generic versions of Alphaderm launch?
Alphaderm is a drug marketed by Bioglan and is included in one NDA.
The generic ingredient in ALPHADERM is hydrocortisone; urea. Additional details are available on the hydrocortisone; urea profile page.
US Patents and Regulatory Information for ALPHADERM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioglan | ALPHADERM | hydrocortisone; urea | CREAM;TOPICAL | 086008-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
ALPHADERM Investment Scenario and Fundamentals Analysis: Market, Exclusivity, Patent Estate, and Generic/Biosimilar Risk
ALPHADERM is marketed in the US as alclometasone dipropionate (a topical corticosteroid). The investment case turns on (1) how ALPHADERM is positioned within topical dermatology, (2) whether patent coverage meaningfully blocks US generics, and (3) how many substitution/launch pathways remain open once exclusivity and exclusory periods end.
What follows is an investment-grade fundamentals view focused on US IP/regulatory barriers, launch risk, pricing pressure, and commercial sustainability. If ALPHADERM is the same product name used by different labelers across regions, this analysis still applies only to the FDA-regulated US scenario for a topical corticosteroid product using alclometasone dipropionate.
What is ALPHADERM (alclometasone dipropionate) and how is it used in dermatology?
ALPHADERM is a topical corticosteroid indicated for inflammatory dermatoses responsive to corticosteroids. As with other mid-potency topical steroids in this class, demand is driven by:
- Primary care and dermatology prescribing for eczema/dermatitis-like conditions
- Formulation preference (ointment vs cream vs lotion vehicle affects adherence and tolerability)
- Insurance coverage and tier placement for “preferred” topical steroid SKUs
Which formulations matter for investment value?
For topical corticosteroids, commercial outcomes hinge on formulation and presentation:
- Cream/ointment vs lotion/gel: vehicle can shift patient acceptance and prescriber switching
- Tube size and NDC coverage: affects PBM contracting, co-pay tiers, and substitution
What patents protect ALPHADERM and how strong is the patent estate for US exclusivity?
A topical corticosteroid with a long commercial history typically has weak incremental patent leverage by the time modern generics are available. For an investment thesis, the key question is not whether patents exist, but whether they:
- Cover the marketed product (same active, same dosage form, same formulation features), and
- Remain unexpired in the US and
- Are listed in the Orange Book against the exact NDA/NDC that corresponds to ALPHADERM.
How to evaluate ALPHADERM’s patent estate quickly
A practical patent strength screen for investment decisions:
- Orange Book listing count: more listed patents can mean more barriers, but it often also reflects blockable formulation “granularity”.
- Last expiration dates: the latest expiring patent listed to the relevant drug product is the practical “hard stop” for fully blocking generic substitution.
- Whether listed patents are product/process vs method-of-use vs polymorph/formulation:
- Product/formulation patents are easier to design around for generics through “non-infringing” changes.
- Method-of-use patents can be blocked if labeling is enforced, but for topical steroids, generic substitution usually targets product labeling scope.
Patent estate implications for investment
For a mature class like topical corticosteroids, the investment-relevant pattern is usually:
- Original compound and early process patents long expired
- Remaining value from later formulation or manufacturing improvements
- If those are not meaningfully tied to the marketed presentation, generic erosion is the base case
When does ALPHADERM lose exclusivity in the US (Orange Book and patent expiration timing)?
The exclusivity path for a generic-facing small molecule product normally matters in two layers:
- Regulatory exclusivities (Orange Book “Exclusivity” codes, if applicable)
- Patent term for listed patents against the drug product
Investment timing framework
For a topical steroid, generic pressure usually accelerates around:
- Patent expiry of the last-listed blocking patent for the specific NDA/NDC
- Settlement-triggered launch windows (if an ANDA litigation settlement occurred)
- PBM contract transitions after generic availability stabilizes
What this means for fundamentals
In investment modeling, topical steroids are high sensitivity to:
- Post-LOE price compression
- Volume substitution to cheaper equivalents
- Loss of payer preference
Is there Paragraph IV ANDA litigation risk for ALPHADERM generics?
The risk profile depends on whether ALPHADERM has:
- Unexpired Orange Book patents suitable for Paragraph IV certifications, or
- Prior ANDA litigations that set precedent and signal future challenges.
What litigation changes in the base-case
- If the last listed patents are unexpired and actively enforced, Paragraph IV challenges can delay generic entry via injunction/settlement.
- If listed patents are expired or easily design-around, generic challengers may file early and settle for smaller market-impact outcomes.
Investment relevance
Topical steroids are typically rapidly commoditized once generics enter. Even when injunctions delay entry, settlements often end with:
- A “carve-out” of a fraction of sales or
- A delayed launch date that still culminates in eventual full-market penetration.
What generic entry risks exist for ALPHADERM (ANDA design-around, labeling, and substitution)?
Key design-around levers
For topical corticosteroids, generic developers typically focus on:
- Bioequivalence/BA (systemic absorption is limited, but formulation can affect local exposure)
- Vehicle matching (cream vs ointment vs lotion)
- Labeling scope (ensuring the generic’s indication language matches the cleared label status)
Substitution dynamics
Once a generic is approved and covered:
- Pharmacists commonly substitute at point of dispensing.
- PBMs drive formulary placement, which accelerates switching.
Investment implication
If ALPHADERM has no durable formulation differentiation that survives generic equivalence requirements, the probability-weighted outcome is:
- Price erosion
- Margin compression
- Working capital pressure from reduced purchasing power over time
What formulations are protected by ALPHADERM patents (cream vs ointment vs other vehicles)?
For investment diligence, the most relevant question is:
- Are the protected features tied to the specific marketed vehicle?
Typical categories of formulation protection that matter for topical steroids:
- Rheology and spreadability
- Preservative system
- Emulsifier system
- Particle dispersion and suspension stability
- Permeation enhancers (if present)
Commercial consequence
If a later patent protects a vehicle-specific feature and the generic cannot match without infringement, it can delay entry for that specific presentation. If not, generic entry is usually presentation-flexible.
How does ALPHADERM compare with other topical corticosteroids (potency, payer preference, and switching)?
Topical steroid competition clusters around:
- Potency class
- Vehicle preference
- Brand-to-generic switching
- Plan formularies
Investment insight
Even if ALPHADERM is branded, in topical dermatology most brands face:
- Early substitution once generics clear
- Slow rebound unless a meaningful differentiation exists (novel delivery system, superior tolerability, stronger payer positioning)
What is the competitive landscape for alclometasone dipropionate topical products?
The competitive environment typically includes:
- Multiple generic SKUs with the same active ingredient
- Occasional brand relaunches or reformulations where they can re-enter at higher prices for limited plan segments
What to monitor
- NDC-level pricing trends
- Number of approved equivalents
- PBM formulary placement (tier migration)
How strong is the manufacturing and IP barrier for ALPHADERM (process patents, know-how, and scale)?
For topical drugs, process barriers can exist but usually do not fully block generic manufacturing because:
- Formulation scale is standard in dermatology manufacturing
- Equipment and process steps are replicable
- Process patents can be enforceable only if they define manufacturing steps not used by the generic
Investment implication
Without strong process patents still in force, manufacturing barriers mostly translate into:
- Transitional supply constraints
- Quality system hurdles
- Not sustained price protection
What FDA status and regulatory pathways affect ALPHADERM investment (NDA vs ANDA vs 505(b)(2))?
For branded topical drugs, generic pathways are usually:
- ANDA (if an adequate reference product exists)
- 505(b)(2) (if there is a formulation change or bridging strategy requiring partial reliance)
Investment relevance
- If ALPHADERM is in a legal/Orange Book environment with unexpired listed patents, ANDA challengers face certification strategy that can drive litigation and settlement delays.
- If patents are expired, entry becomes a timeline question: approval time plus PBM contracting.
What Orange Book status does ALPHADERM have (listed patents, exclusivity codes, and expiration dates)?
The Orange Book is the actionable source for:
- Listed patent numbers against the relevant NDA/NDC
- Expiration dates that control generic entry timing
- Any granted exclusivity periods
Investment modeling input
For valuation, the critical fields to model are:
- Latest patent expiration for the exact drug product
- Any remaining exclusivity
- History of Paragraph IV filings tied to the same NDA
What business and licensing dynamics matter most for ALPHADERM (distribution, relaunches, and contract-driven revenue)?
Branded topical dermatology revenue is frequently shaped less by clinical superiority and more by:
- PBM rebates
- Channel mix
- Contracting velocity
- NDC breadth (how many dosage forms and pack sizes are kept in preferred coverage)
Investment implication
The revenue curve depends on:
- How quickly generic penetration reaches formulary and shelf substitution
- Whether ALPHADERM can maintain a “preferred brand” position long enough to amortize marketing and trade spend
Key Takeaways
- ALPHADERM, as alclometasone dipropionate, competes in a commoditizing topical corticosteroid market where durability depends on Orange Book-listed patent coverage tied to the specific marketed formulation.
- Investment upside is most plausible when the latest unexpired listed patent(s) meaningfully cover the exact vehicle/presentation and have a credible enforcement record.
- Base-case risk is rapid generic price compression after loss of patent/exclusivity barriers for the relevant NDA/NDC.
- The valuation-critical timeline is the latest expiration date of listed patents and any litigation-set settlement launch windows for equivalent products.
FAQs
-
How do I estimate ALPHADERM revenue sensitivity to generic entry?
Model payer tier migration and NDC-level switching rates; assume steep price compression in the first 6 to 18 months after approved generics reach preferred formulary status. -
Does alclometasone dipropionate topical generics face bioequivalence hurdles that could delay launch?
Typically the key constraints are formulation/vehicle similarity and regulatory bridging requirements; manufacturing scale alone usually does not stop approval if the reference product is well characterized. -
What patent types most effectively delay generic competition for topical steroids?
Vehicle-specific formulation patents or enforceable product claims that cannot be designed around while maintaining equivalent therapeutic performance. -
What settlement signals predict whether generics will enter quickly after litigation?
Settlement terms that specify broad non-entry commitments end with earlier launch dates for most SKUs; narrower carve-outs delay only certain presentations. -
Which commercial KPI best forecasts long-term ALPHADERM margin under generic pressure?
Gross-to-net trend driven by rebate and contracting changes after generic substitution accelerates, tracked at NDC level.
References (APA)
- U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
- U.S. Food and Drug Administration. (n.d.). Drug Approval Reports and related regulatory information. FDA. https://www.fda.gov/drugs/drug-approvals-and-databases
- U.S. Federal Trade Commission. (n.d.). Overview of ANDA settlements and competitive effects (resources). FTC. https://www.ftc.gov/
More… ↓
